Mode
Text Size
Log in / Sign up

Neuromuscular electrostimulation plus swallowing therapy may benefit dysphagia in severely disabled MS patientsCan electrical stimulation help people with MS swallow more easily?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider NMES with swallowing therapy for dysphagia in severely disabled MS patients, but evidence is from a single moderate-sized RCT.

This randomized controlled trial evaluated traditional swallowing therapy plus neuromuscular electrostimulation (TST-NMES) versus therapy plus sham stimulation (TST-S) in 101 people with multiple sclerosis and dysphagia. Both treatment groups showed improvement in dysphagia disturbances over time, though specific effect sizes and statistical measures were not reported. The study found significantly greater gains in ASHA scores among severely disabled patients (EDSS ≥7) who received NMES compared to sham. Baseline ASHA scores predicted outcomes, while EDSS influenced outcomes only in the control group.

Treatment safety and tolerability were confirmed, with no adverse effects reported during the study. Serious adverse events and discontinuation rates were not specified in the abstract.

Key limitations include the moderate sample size and lack of reported primary outcome, effect sizes, and confidence intervals. The main benefit was observed only in a severity subgroup (EDSS ≥7), and the abstract notes these results support further investigation in larger trials. For clinical practice, NMES combined with standard swallowing therapy appears feasible and may offer particular benefit for more disabled patients with MS-related dysphagia, though broader application requires additional evidence.

Imagine the simple act of swallowing becoming a daily struggle. For many people living with multiple sclerosis (MS), this is a real and distressing problem called dysphagia. Researchers wanted to see if adding a gentle electrical stimulation to the throat muscles—a technique called neuromuscular electrostimulation (NMES)—could boost the benefits of standard swallowing therapy.

They studied 101 people with MS and swallowing problems. Everyone received traditional swallowing therapy. Half also received the real NMES, while the other half received a sham (fake) stimulation. Over time, both groups got better at swallowing. But the story changed when researchers looked specifically at people with more severe physical disability from their MS. In that group, those who got the real electrical stimulation showed significantly greater improvements in their swallowing scores.

The treatment appeared safe and well-tolerated, with no reported adverse effects. However, it's important to note that the main benefit was only clear for people with more advanced MS. The study was moderate in size, and the abstract doesn't provide detailed numbers on how much better the improvement was. The researchers themselves say these results support the need for larger trials to investigate further.

What this means for you:
Electrical stimulation may boost swallowing therapy for people with more severe MS.

Study Details

Study typeRct
Sample sizen = 52
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Dysphagia is a common and potentially life-threatening complication in people with multiple sclerosis (pwMS), even in early disease stages. Although compensatory strategies may reduce aspiration risk, they do not restore normal swallowing. Neuromuscular Electrical Stimulation (NMES) has shown promise in dysphagic populations, but evidence in pwMS is scarce. OBJECTIVES: This double-blind, randomized, placebo-controlled trial aimed to evaluate the feasibility and added benefit of NMES combined with standard swallowing therapy in pwMS with dysphagia. RESULTS: Of 151 dysphagic pwMS screened, 101 were enrolled and randomized to receive NMES plus conventional swallowing exercises (TST-NMES) (n = 52) or sham stimulation with the same therapy (TST-S) (n = 49). Both groups improved in dysphagia disturbances over time. However, when we analysed the two groups according to disease severity, significantly greater ASHA score gains were observed in severely disabled patients (EDSS ≥7) receiving NMES. Baseline ASHA predicted outcomes, while EDSS influenced only controls. At follow-up, no adverse effects were reported, confirming treatment safety and tolerability. CONCLUSION: NMES combined with standard swallowing therapy appears to be a feasible and effective intervention for dysphagia in pwMS, especially in more disabled people. These results support further investigation in larger randomized trials.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.